Aaruha Technology Fund

Aaruha Technology Fund is a Bengaluru-based early-stage venture firm that has explicitly positioned itself around AI-enabled enterprise and software companies in India. Checks land in the $250k to $1M range, with the firm willing to lead small seeds and participate alongside larger leads at Series A. For healthcare AI founders, Aaruha sits in a useful slot: large enough to anchor a meaningful seed round, small enough to engage substantively with a single product, and explicitly aligned with AI rather than treating it as a buzzword applied to a generalist portfolio.

The healthcare/AI thesis is read off the firm’s stated focus on AI-enabled enterprises and software products in India, with sub-vertical attention to AI/ML in healthcare and Health IT software. That framing tilts the firm toward B2B and B2B2C plays with clear enterprise buyers, hospital systems, payers, diagnostics chains, and pharma and away from pure consumer wellness. Founders building infrastructure software, clinical workflow tools, AI documentation, RCM automation, and diagnostics support will find more thesis fit than DTC supplement brands or patient apps.

Geographically, Aaruha’s regional advantage is its embeddedness in the Bengaluru ecosystem, which remains the densest concentration of healthcare and AI engineering talent in India. The right founder profile is a technical team building software with a credible distribution path into Indian or Indian-diaspora enterprise customers, or India-built software that is already showing pull from US or Middle Eastern buyers. A US-only commercial strategy with no India play is a weaker fit; better-positioned funds exist on the West Coast for that.

Intros are best routed through other Indian seed-stage VCs, accelerator program leads (T-Hub, NSRCEL, IIT alumni networks), or a portfolio founder. A cold email is workable if it leads with a specific AI thesis, a working product, and an early customer letter rather than a deck. The pitch should center on the AI moat, the data flywheel, and the wedge into a defined enterprise buyer. Lead with the most concrete commercial proof point you have.

Caveats to weigh. Aaruha’s public footprint is thinner than that of the marquee Indian seed firms, which cuts two ways: less brand pull on follow-on rounds, but more founder-aligned attention. Confirm the firm’s actual healthcare engagement by speaking to two existing portfolio founders before taking term sheets, especially around regulatory comfort with clinical products and the firm’s behavior in hard quarters. Founders raising larger rounds (above $2M priced seed or anything Series A+ from a single lead) should look beyond Aaruha as the lead and instead position it as a value-add co-investor. Honest read: the public record on AI-healthcare-specific deployments is limited enough that diligence should rely on direct reference calls rather than thesis marketing alone.